Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy

Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy

Background: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking. Objectives: This study examines the associatio...

Full description

Bibliographic Details
Main Authors: Anthony F. Yu, MD, Chaya S. Moskowitz, PhD, Katherine Lee Chuy, MD, Ji Yang, MD, Chau T. Dang, MD, Jennifer E. Liu, MD, Kevin C. Oeffinger, MD, Richard M. Steingart, MD
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JACC. CardioOncology
Subjects:
breast cancer
cardiac monitoring
cardio-oncology
cardiotoxicity
heart failure
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087320300703

Internet

http://www.sciencedirect.com/science/article/pii/S2666087320300703

Similar Items